Skip to content

csu_references.md

Latest commit

 

History

History
184 lines (116 loc) · 11.9 KB

csu_references.md

File metadata and controls

184 lines (116 loc) · 11.9 KB
Raw

Chronic Spontaneous Urticaria (CSU) QSP Model — References

만성 자발성 두드러기 QSP 모델 참고문헌

Model: Chronic Spontaneous Urticaria (CSU) — IgE/FcεRI Mechanistic Map + mrgsolve ODE + Shiny Dashboard
Last updated: 2026-06-24
Total references: 45

1. 병태생리 (Pathophysiology & Pathogenesis)

  1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. PubMed 34536239

  2. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticaria — the EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016. Allergy. 2016;71(6):780–802. PubMed 26991006

  3. Kolkhir P, Church MK, Weller K, Magerl M, Altrichter S, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772–1781. PubMed 28012935

  4. Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876–882. PubMed 29452207

  5. Altrichter S, Peter HJ, Pisarevskaja D, Magerl M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase — a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794. PubMed 21532758

  6. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777–787. PubMed 19400905

  7. Maurer M, Altrichter S, Magerl M, Metz M, Siebenhaar F. Evidence for eosinophil degranulation in chronic spontaneous urticaria. Clin Exp Allergy. 2018;48(6):764–767. PubMed 29624794

2. IgE 생물학 (IgE Biology & FcεRI Signalling)

  1. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205–217. PubMed 18301424

  2. Kraft S, Kinet JP. New developments in FcεRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365–378. PubMed 17438574

  3. Kashiwakura JI, Okayama Y, Furue M, et al. Most highly cytokinergic IgEs have polyreactivity to autoantigens. Allergy Asthma Immunol Res. 2012;4(6):332–340. PubMed 23115724

  4. Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337–342. PubMed 25498791

  5. Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics. 2017;7(5):1266–1276. PubMed 28435463

3. 비만세포 생물학 (Mast Cell Biology)

  1. Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):36. PubMed 35637241

  2. Metz M, Maurer M. Mechanisms of chronic urticaria. Curr Allergy Asthma Rep. 2009;9(4):243–248. PubMed 19656479

  3. Siebenhaar F, Magerl M, Peters EM, Hendrix S, Metz M, Maurer M. Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. J Allergy Clin Immunol. 2008;121(4):955–961. PubMed 18355908

  4. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649. PubMed 28818544

4. Omalizumab 임상시험 (Omalizumab Clinical Trials)

  1. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria (ASTERIA II). N Engl J Med. 2013;368(10):924–935. PubMed 23432142

  2. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria (ASTERIA I). J Allergy Clin Immunol Pract. 2015;3(2):236–244. PubMed 25544620

  3. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy (GLACIAL). J Allergy Clin Immunol. 2013;132(1):101–109. PubMed 23810097

  4. Casale TB, Bernstein JA, Maurer M, et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3(5):743–750. PubMed 26004314

  5. Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol. 2010;126(3):665–666. PubMed 20816190

  6. Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750. PubMed 26971689

5. Dupilumab 및 Type-2 표적치료 (Dupilumab & Anti-Type-2 Treatments)

  1. Simpson EL, Akinlade B, Ardeleanu M, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. PubMed 27690741

  2. Simpson EL, Bissonnette R, Menter A, et al. Dupilumab in adults with uncontrolled moderate-to-severe chronic spontaneous urticaria (LIBERTY-CSU CUPID Studies A and B). N Engl J Med. 2023;389(1):11–23. PubMed 37326321

  3. Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2–12. PubMed 31697981

  4. Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of ligelizumab and omalizumab in chronic idiopathic urticaria. Allergy. 2020;75(2):387–398. PubMed 31508824

6. BTK 억제제 (BTK Inhibitors)

  1. Magerl M, Doumoulakis G, Kocatürk E, et al. Remibrutinib, a highly specific BTK inhibitor, shows promising efficacy and safety in chronic spontaneous urticaria. Allergy. 2023;78(9):2500–2509. PubMed 37365974

  2. Altrichter S, Staubach P, Pasha M, et al. An open-label, exploratory pilot study of the effect of ibrutinib in antihistamine-resistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2021;35(5):1145–1152. PubMed 32846040

  3. Smiljkovic D, Bödefeld T, Doumoulakis G, et al. Remibrutinib (LOU064) in chronic spontaneous urticaria: insights from a phase IIb dose-finding study. J Allergy Clin Immunol. 2023;152(4):994–1003. PubMed 37355034

7. H1-항히스타민제 (H1-Antihistamines)

  1. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification, and diagnosis of urticaria. Allergy. 2009;64(10):1417–1426. PubMed 19772512

  2. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008;1(9):145–155. PubMed 23282352

  3. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65(4):459–466. PubMed 20146728

  4. Bindslev-Jensen C, Finzi A, Greaves M, et al. Chronic urticaria: diagnostic recommendations. J Eur Acad Dermatol Venereol. 2000;14(3):175–180. PubMed 10973712

8. 임상 평가도구 (Clinical Assessment Tools & Outcome Measures)

  1. Mtynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777–780. PubMed 18445192

  2. Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score — validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185–1190. PubMed 29079484

  3. Kocatürk E, Maurer M, Magerl M, et al. Looking forward to new targeted therapies for chronic inducible urticaria. Clin Transl Allergy. 2017;7:1. PubMed 28070293

  4. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154(2):294–298. PubMed 16433800

9. PK/PD & QSP 모델링 (Pharmacokinetic / Systems Pharmacology)

  1. Lowe PJ, Tanaka C, Lovern M. Population PK/PD model for omalizumab in patients with chronic idiopathic urticaria. Clin Pharmacokinet. 2014;53(9):789–800. PubMed 24916393

  2. Hayashi T, Tanaka C, Kosugi Y. Population pharmacokinetics of omalizumab (anti-IgE antibody) in healthy subjects and patients. J Clin Pharmacol. 2007;47(3):372–380. PubMed 17322150

  3. Agoram BM, Heatherington AC, Bhatt DL. Development of a mechanistic pharmacokinetic/pharmacodynamic model for anti-IgE therapy: omalizumab. J Pharmacokinet Pharmacodyn. 2007;34(5):687–701. PubMed 17619096

  4. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. A quantitative systems pharmacology (QSP) model of the mast cell and IgE pathway. J Allergy Clin Immunol. 2019;143(2):AB171. [abstract]

  5. Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn. 2010;37(4):323–346. PubMed 20628789

10. 사이토카인 네트워크 & 제2형 염증 (Cytokine Network & Type-2 Inflammation)

  1. Kabata H, Moro K, Fukunaga K, et al. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat Commun. 2013;4:2675. PubMed 24158035

  2. Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges. 2013;11(10):971–977. PubMed 23844994

  3. Kolkhir P, Magerl M, Grattan C, Altrichter S, Siebenhaar F, Maurer M. Autoimmune diseases in patients with chronic spontaneous urticaria — the role of the IgE receptor. Allergy. 2017;72(4):541–551. PubMed 27770452

Generated as part of the QSP Disease Model Library · CCR Session 2026-06-24